首页> 外国专利> Direct effect of extracted BMP on Mesenchymal Stem Cell Differentiation for use in a Culture Medium, Diagnostic Assay, and Adjunct or Stand-Alone Pharmaceutical Treatment

Direct effect of extracted BMP on Mesenchymal Stem Cell Differentiation for use in a Culture Medium, Diagnostic Assay, and Adjunct or Stand-Alone Pharmaceutical Treatment

机译:提取的BMP对间充质干细胞分化的直接影响,用于培养基,诊断分析以及辅助或独立的药物治疗

摘要

The present invention comprises a culture medium composition for the proliferation and differentiation of mesenchymal stem cells into osteoblasts, the composition comprising a bone morphogenic protein (BMP) complex with TGF-f3, bFGF, VEGF, and IGF, bound to collagen type 1 dissolved into a mesenchymal stem cell culture medium. Methods of use of the composition and/or the BMP complex comprise: performing a diagnostic assay detecting a level of bone morphogenetic proteins in a patient serum level; determining if the BMP level is below a threshold level; and when the BMP level is below the threshold level, administering a composition comprising a BMP complex, with or without a pharmaceutical, such as a drug for treating and/or preventing osteoporosis. The present invention comprises performing an in vivo lavage and bone assay; and administering the BMP complex composition to a patient in need thereof.
机译:本发明包括用于将间充质干细胞增殖和分化成成骨细胞的培养基组合物,该组合物包含与TGF-f3,bFGF,VEGF和IGF结合的骨形态发生蛋白(BMP)复合物,该复合物结合到溶解于其中的1型胶原。间充质干细胞培养基。所述组合物和/或BMP复合物的使用方法包括:进行诊断测定以检测患者血清水平中骨形态发生蛋白的水平;确定BMP水平是否低于阈值水平;当BMP水平低于阈值水平时,给予包含BMP复合物的组合物,所述组合物具有或不具有药物,例如用于治疗和/或预防骨质疏松的药物。本发明包括进行体内灌洗和骨测定;将BMP复合物组合物给予有需要的患者。

著录项

  • 公开/公告号US2020224167A1

    专利类型

  • 公开/公告日2020-07-16

    原文格式PDF

  • 申请/专利权人 ZYCAL BIOCEUTICALS INC.;

    申请/专利号US201916708169

  • 发明设计人 DAN TRIPODI;

    申请日2019-12-09

  • 分类号C12N5/077;C12N5;

  • 国家 US

  • 入库时间 2022-08-21 11:25:56

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号